Pliant Therapeutics

Today we announced our presentations at the upcoming 2024 EASL | The Home of Hepatology Congress. https://ir.pliantrx.com/news-releases/news-release-details/pliant-therapeutics-announces-upcoming-presentations-european

Today we announced our First Quarter 2024 Financial Results and provided a company update. Review our progress to date and the milestones for 2024:
https://ir.pliantrx.com/news-releases/news-release-details/pliant-therapeutics-provides-corporate-update-and-reports-11

Pliant team members will participate in investor events throughout May hosted by RBC, Stifel and Piper Sandler. Learn more: https://ir.pliantrx.com/news-releases/news-release-details/pliant-therapeutics-participate-upcoming-investor-events-4

The patient is center to everything we do at Pliant. We look forward to participating in this important event hosted by the European Pulmonary Fibrosis Federation (EU-PFF). Learn more: https://lnkd.in/gVvVRyYw

At Pliant, we learn from our colleagues. Our Plianteers recently gathered for a roundtable discussion with our CHRO Lily Cheung, our CDO Minnie Kuo and our CRO S. Mishima Gerhart to discuss their careers, the importance of mentorship and what brought them to biotech and Pliant.

Pliant is proud to recognize and support a time to raise awareness about liver health and the worldwide prevalence of liver disease. Learn about this international campaign:
https://easl.eu/news/wld2024/

One of the benefits of working at Pliant is our commitment to overall wellness. From physical and mental to financial and social well-being, we believe these are key to a strong and vibrant workplace culture. Learn more about the benefits of working with us: https://pliantrx.com/careers/

Pliant team members will participate in investor events hosted by Needham & Company and Piper Sandler. Listen to the Needham fireside chat live or by replay at: https://lnkd.in/gkFKVG32

Today we announced four upcoming presentations at the American Thoracic Society's 2024 International Conference, taking place May 17-22 in San Diego, California. Review the abstracts: https://lnkd.in/gn4TY6DZ

Today we announced the accelerated bexotegrast development plan for the treatment of idiopathic pulmonary fibrosis with the implementation of a pivotal, adaptive Phase 2b/3 trial. Learn more: https://lnkd.in/gSndMqTK

On this National we want to give a heartfelt thanks to our dedicated employees who make Pliant a very special place to work. Thank you Team Pliant!

In honor of Black History Month, Pliant’s Committee hosted speaker Roslyn Daniels, President and Founder of Black Health Matters. Roslyn, thank you for the highly engaging discussion on health, wellness and health disparities within the Black American community! To learn more about the great work of BHM, visit: https://blackhealthmatters.com/about-us/

Today we announced our Fourth Quarter 2023 Financial Results and provided a company update. Review our progress and milestones for 2024: https://ir.pliantrx.com/news-releases/news-release-details/pliant-therapeutics-provides-corporate-update-and-reports-10

Pliant team members will participate in fireside chats at upcoming investor conferences hosted by TD Cowen and Leerink Partners. Listen live or to the replay at: https://ir.pliantrx.com/events-and-presentations

February 29th is Rare Disease Day, a day when our Plianteers recommit to improving the lives of patients, families and caregivers impacted by rare diseases.

Learn more about the science behind our leading position in the rare fibrotic diseases of IPF and PSC: https://pliantrx.com/our-science/

Recognizing the International Day of Women and Girls in Science and in support of Life Science Cares Bay Area and Science from Scientists, our Plianteers assembled 500 activity test kits with the goal of inspiring young scientific minds.

We are accepting applications for our 2024 Summer Internship Program. If you are a current undergraduate, graduate or law school student seeking an opportunity to gain working experience in a dynamic biopharmaceutical company, please review our openings and apply. https://pliantrx.com/jobs/

Today we announced that we will participate in upcoming investor events hosted by Oppenheimer & Co. Inc. and Wells Fargo. Learn more: https://ir.pliantrx.com/news-releases/news-release-details/pliant-therapeutics-participate-upcoming-investor-events-2

We are pleased to share additional positive data from our Phase 2a INTEGRIS-PSC trial in patients with primary sclerosing cholangitis. Review the details: https://lnkd.in/gfjfPuBf

Our Plianteers kicked off 2024 with volunteer efforts in support of the incredible work of the Sf-Marin Food Bank and Second Harvest of Silicon Valley by distributing food to our San Francisco and South San Francisco neighbors. We are grateful to be able to give back to our communities and for the important role that volunteerism holds in our culture.

Join our CEO, Dr. Bernard Coulie, at the 42nd Annual J.P. Morgan Healthcare Conference with a review of our 2023 achievements and 2024 milestones in a presentation on Tuesday, January 9 at 7:30 a.m. PT. https://ir.pliantrx.com/news-releases/news-release-details/pliant-therapeutics-participate-42nd-annual-jp-morgan-healthcare

Our Plianteers enjoy sharing their experiences of being a part of . Learn about our dynamic culture and the benefits to working at Pliant, recognized as a 2023 Best Places to Work. https://lnkd.in/gjPhTFf

Join a passionate team committed to delivering novel treatments to improve patient's lives. Learn more about these and other opportunities to be a part of : https://pliantrx.com/jobs/

Excited to share the positive interim results from our INTERGRIS-PSC Phase 2a trial evaluating bexotegrast in patients with primary sclerosing cholangitis, or PSC, as part of tonight's late-breaking oral presentation at the AASLD's The Liver Meeting®. We were pleased to have Dr. Gideon Hirschfield share these results this evening at this leading hepatic conference. Review all three of our posters: https://lnkd.in/gwJqB-D5

Join members of this week at the 2023 PFF Summit hosted by the Pulmonary Fibrosis Foundation. We are proud to be a Gold Sponsor of this event. Visit our booth and learn about BEACON-IPF, our clinical trial enrolling patients in IPF.

Today we presented our third quarter 2023 financials and provided a company update. Read about our 2023 accomplishments and 2024 milestones. https://ir.pliantrx.com/news-releases/news-release-details/pliant-therapeutics-provides-corporate-update-and-reports-9

Today we announced that we will participate in upcoming conferences hosted by Stifel, Evercore and PiperSandler. See details on the fireside chats: https://ir.pliantrx.com/news-releases/news-release-details/pliant-therapeutics-participate-upcoming-investor-conferences-7

Teams presented three posters highlighting PLN-101095, a novel inhibitor of integrins αvβ8, and αvβ1, at the Society for Immunotherapy of Cancer (SITC) Annual Meeting. More on these presentations: https://ir.pliantrx.com/news-releases/news-release-details/pliant-therapeutics-presentations-annual-meeting-society

Looking forward to sharing our work with the oncology community this week at the Society for Immunotherapy of Cancer's Annual Meeting. View the abstracts: https://ir.pliantrx.com/news-releases/news-release-details/pliant-therapeutics-announces-three-presentations-annual-meeting